Monolithic LC method applied to fesoterodine fumarate low dose extended-release tablets: Dissolution and release kinetics

Costa, 2001, Modeling and comparison of dissolution profiles, Eur. J. Pharm. Sci., 13, 123, 10.1016/S0928-0987(01)00095-1 Dash, 2010, Kinetic modeling on drug release from controlled drug delivery systems, Acta Pol. Pharm. Drug Res., 67, 217 Gao, 2011, Mathematical modeling of variables involved in dissolution testing, J. Pharm. Sci., 100, 4934, 10.1002/jps.22673 Malhotra, 2008, Pharmacokinetic profile of fesoterodine, Int. J. Clin. Pharmacol. Ther., 46, 556, 10.5414/CPP46556 Chapple, 2008, The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis, Eur. Urol., 54, 543, 10.1016/j.eururo.2008.06.047 Parekha, 2013, Investigation of ex vivo stability of fesoterodine in human plasma and its simultaneous determination together with its active metabolite 5-HMT by LC–ESI-MS/MS: application to a bioequivalence study, J. Chromatogr. B, 913–914, 1, 10.1016/j.jchromb.2012.11.010 Michel, 2008, Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome, Expert. Opin. Pharmacother., 9, 1787, 10.1517/14656566.9.10.1787 Food and Drug Administration, Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of in vitro/in vivo Correlations, Rockville, 1997, pp. 1–27. Sakore, 2011, In vitro-in vivo correlation (IVIVC): a strategic tool in drug development, J. Bioequiv. Availab., S3, S1 Yáñez, 2011, Flip-flop pharmacokinetics --- delivering a reversal of disposition: challenges and opportunities during drug development, Ther. Deliv., 2, 643, 10.4155/tde.11.19 Sangoi, 2011, Fesoterodine stress degradation behavior by liquid chromatography coupled to ultraviolet detection and electrospray ionization mass spectrometry, Talanta, 84, 1068, 10.1016/j.talanta.2011.03.018 Sangoi, 2010, Determination of fesoterodine in pharmaceutical formulations by using liquid chromatography–tandem mass spectrometry, Eur. J. Mass Spectrom., 16, 653, 10.1255/ejms.1103 Sangoi, 2012, Second-order derivative UV spectrophotometric method for the determination of fesoterodine and comparison with LC, CE and LC-MS/MS in commercial extended-release tablets, Acta Chim. Slov., 59, 136 Sangoi, 2013, Determination of fesoterodine in pharmaceutical preparations by stability-indicating capillary zone electrophoresis method, J. AOAC Int., 96, 1308, 10.5740/jaoacint.11-082 United States Pharmacopoeia, 34th ed., 〈711〉 Dissolution, United States Pharmacopoeial Convention, Rockville, 2011, pp. 1–8. ICH Guidelines, Q2 (R1): Validation of analytical procedures: text and methodology, in: International Conference on Harmonisation, Geneva, Switzerland, 2005, pp. 1–13. United States Pharmacopoeia, Pharmacopeial Forum, 30, 2004, pp. 351–363. Higuchi, 1963, Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices, J. Pharm. Sci., 52, 1145, 10.1002/jps.2600521210 Grassi, 2005, Mathematical modelling and controlled drug delivery: matrix systems, Curr. Drug Deliv., 2, 97, 10.2174/1567201052772906